birociclib
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started May 22, 2018 (NCT04539496)
Timeline
Indications
Mechanism of action
- Cyclin-dependent kinase 4INHIBITOR
CDK4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05478109 | Phase 1 | Aug 2, 2022 | Xuanzhu Biopharmaceutical Co., Ltd. |
| NCT05257395 | Phase 3 | Feb 28, 2022 | Harbin Medical University, Xuanzhu Biopharmaceutical Co., Ltd. |
| NCT05077449 | Phase 3 | Nov 30, 2021 | Chinese Academy of Medical Sciences, Xuanzhu Biopharmaceutical Co., Ltd. |
| NCT04951765 | Phase 1 | Aug 31, 2021 | Xuanzhu Biopharmaceutical Co., Ltd. |
| NCT04951713 | Phase 1 | Jul 31, 2021 | Xuanzhu Biopharmaceutical Co., Ltd. |
| NCT04539496 | Phase 1/Phase 2 (Phase 2) | May 22, 2018 | Sihuan Pharmaceutical Holdings Group Ltd. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xuanzhu Biopharmaceutical Co., Ltd. | For profit | 5 | 5 | 2 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Harbin Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Sihuan Pharmaceutical Holdings Group Ltd. | For profit | 1 | 1 | 1 | 2018 |
4 organizations
Page 1 / 1